Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Betere uitkomsten COVID-19 dankzij therapeutische antistolling
sep 2021 | Benigne hematologie, Pneumonie, Virale infecties